里昂发表报告指出,药明康德(02359.HK) (603259.SH) 2025年第二季收入及经调整非国际财务报告准则净利润分别按年增长20%及48%,符合2025年7月10日发布的盈利预告。公司将2025年持续经营业务收入增长指引,从10%至15%上调至13%至17%,自由现金流指引从40亿元至50亿元人民币,上调到50亿元至60亿元人民币。考虑到上半年强劲表现,上调后的收入指引并不显激进,并...
Source Link里昂发表报告指出,药明康德(02359.HK) (603259.SH) 2025年第二季收入及经调整非国际财务报告准则净利润分别按年增长20%及48%,符合2025年7月10日发布的盈利预告。公司将2025年持续经营业务收入增长指引,从10%至15%上调至13%至17%,自由现金流指引从40亿元至50亿元人民币,上调到50亿元至60亿元人民币。考虑到上半年强劲表现,上调后的收入指引并不显激进,并...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.